NasdaqCM - Nasdaq Real Time Price USD

NeoGenomics, Inc. (NEO)

Compare

14.77

-3.84

(-20.63%)

At close: January 10 at 4:00:01 PM EST

14.90

+0.13

+(0.88%)

After hours: January 10 at 7:15:12 PM EST

NeoGenomics Announces Chief Executive Officer Succession

FT. MYERS, Fla., January 10, 2025--NeoGenomics' Chris Smith will retire as CEO and board member, effective April 1, 2025. Tony Zook will assume the role of CEO at that time.

Business Wire 2 days ago

NEO
-20.63%
NeoGenomics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

FT. MYERS, Fla., January 06, 2025--NeoGenomics will attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.

Business Wire 6 days ago

NEO
-20.63%
NeoGenomics (NEO) Upgraded to Buy: Here's Why

NeoGenomics (NEO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 13 days ago

NEO
-20.63%
NeoGenomics’ Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma

FT. MYERS, Fla., December 11, 2024--NeoGenomics' newly published study shows how ctDNA in MRD may enable earlier identification of disease recurrence for high-risk melanoma patients.

Business Wire last month

NEO
-20.63%
NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting

FT. MYERS, Fla., December 09, 2024--NeoGenomics will present research on hematologic malignancies and the prognostic effects of microenvironment signatures in primary CNS lymphoma at ASH

Business Wire last month

NEO
-20.63%
NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment

FT. MYERS, Fla., November 19, 2024--NeoGenomics will present four abstracts at the Association for Molecular Pathology 2024 Annual Meeting & Expo, November 19-23 (booth #830).

Business Wire last month

NEO
-20.63%
Felicia Williams Joins NeoGenomics Board of Directors

FORT MYERS, Fla., November 14, 2024--NeoGenomics announced the appointment of Felicia Williams to its Board of Directors.

Business Wire last month

NEO
-20.63%
NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference

FT. MYERS, Fla., November 08, 2024--NeoGenomics will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference in New York City.

Business Wire 2 months ago

NEO
-20.63%
NeoGenomics (NEO) Upgraded to Strong Buy: Here's What You Should Know

NeoGenomics (NEO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks 2 months ago

NEO
-20.63%
NeoGenomics Third Quarter 2024 Earnings: EPS Beats Expectations

NeoGenomics ( NASDAQ:NEO ) Third Quarter 2024 Results Key Financial Results Revenue: US$167.8m (up 10% from 3Q 2023...

Simply Wall St. 2 months ago

NEO
-20.63%
Q3 2024 Neogenomics Inc Earnings Call

Q3 2024 Neogenomics Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

NEO
-20.63%
NeoGenomics Inc (NEO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...

NeoGenomics Inc (NEO) reports a 10% revenue increase and unveils new products amid challenges in the Advanced Diagnostics segment.

GuruFocus.com 2 months ago

NEO
-20.63%
NeoGenomics (NEO) Reports Q3 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for NeoGenomics (NEO) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks 2 months ago

NEO
-20.63%
NeoGenomics: Q3 Earnings Snapshot

NEO) on Tuesday reported a loss of $17.7 million in its third quarter. The Fort Myers, Florida-based company said it had a loss of 14 cents per share. Earnings, adjusted for stock option expense and amortization costs, were 5 cents per share.

Associated Press Finance 2 months ago

NEO
-20.63%
NeoGenomics Reports Third Quarter 2024 Results

FORT MYERS, Fla., November 05, 2024--NeoGenomics announced its third-quarter results for the period ended September 30, 2024.

Business Wire 2 months ago

NEO
-20.63%
Wall Street Analysts Believe NeoGenomics (NEO) Could Rally 51.29%: Here's is How to Trade

The consensus price target hints at a 51.3% upside potential for NeoGenomics (NEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks 2 months ago

NEO
-20.63%
NeoGenomics gains conditional approval for solid tumour assays in New York

This approval grants immediate commercial access to these diagnostic tests in the state of New York.

Medical Device Network 2 months ago

NEO
-20.63%
NeoGenomics Receives New York State Approval for Neo Comprehensive™ Solid Tumor Test

FT. MYERS, Fla., October 22, 2024--NeoGenomics has received conditional approval from the NYSDOH for its Neo Comprehensive Solid Tumor assay and NeoTYPE DNA & RNA Lung test.

Business Wire 2 months ago

NEO
-20.63%
NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024

FORT MYERS, Fla., October 15, 2024--NeoGenomics will report its third quarter 2024 financial results prior to the open of the U.S. financial markets on Tuesday, Nov. 5, 2024.

Business Wire 2 months ago

NEO
-20.63%
NeoGenomics (NEO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

NeoGenomics (NEO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks 3 months ago

NEO
-20.63%

Performance Overview

Return	NEO	S&P 500
YTD	-12.71%	-1.35%
1-Year	-8.37%	+22.51%
3-Year	-47.34%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

NeoGenomics, Inc. (NEO)

NeoGenomics Announces Chief Executive Officer Succession

NeoGenomics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

NeoGenomics (NEO) Upgraded to Buy: Here's Why

NeoGenomics’ Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma

NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting

NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment

Felicia Williams Joins NeoGenomics Board of Directors

NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference

NeoGenomics (NEO) Upgraded to Strong Buy: Here's What You Should Know

NeoGenomics Third Quarter 2024 Earnings: EPS Beats Expectations

Q3 2024 Neogenomics Inc Earnings Call

NeoGenomics Inc (NEO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...

NeoGenomics (NEO) Reports Q3 Earnings: What Key Metrics Have to Say

NeoGenomics: Q3 Earnings Snapshot

NeoGenomics Reports Third Quarter 2024 Results

Wall Street Analysts Believe NeoGenomics (NEO) Could Rally 51.29%: Here's is How to Trade

NeoGenomics gains conditional approval for solid tumour assays in New York

NeoGenomics Receives New York State Approval for Neo Comprehensive™ Solid Tumor Test

NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024

NeoGenomics (NEO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Performance Overview